Alzheimer's Research & Therapy

Editors-in-Chief

Douglas R Galasko, University of California, San Diego
Todd E Golde, University of Florida
Gordon K Wilcock, University of Oxford

Editorial Board | Instructions for authors | FAQ

Society Affiliations

Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom

Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.

Articles

There has been an error retrieving the data. Please try again.

Improving memory in AD mice

Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).

Alzheimer's Research & Therapy 2013, 5:25
Diagnosing AD before autopsy

Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.

Alzheimer's Research & Therapy 2013, 5:18
Non-transgenic rat models and AD

Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.

Alzheimer's Research & Therapy 2013, 5:17
Targeting norepinephrine

Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.

Alzheimer's Research & Therapy 2013, 5:21
5-HT6 receptors and AD

María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT₆ receptor compounds, resulting in 5-HT₆-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).

Alzheimer's Research & Therapy 2013, 5:15
Neuroprotective effects of D-Ala2GIP

A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.

Alzheimer's Research & Therapy 2013, 5:20
Novel GSM shows promise for AD

A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.

Alzheimer's Research & Therapy 2013, 5:19
View more articles

RSS

News from Alzforum

Larry Sparks, of Alzheimer’s-Cholesterol Fame, Dies at 63

Skin Cancer Linked to Lower AD Risk—But Don't Hit the Beach Just Yet

Study Finds Ways to Predict, Track Huntington’s Disease

Dementia Incidence Said to Drop as Public Health Improves

Ubiquitin System Awry in Ataxia, Intellectual Disability

RSS

Comments

Affiliation correction

Comment on: Kok et al. Alzheimer's Research & Therapy 2011, 3:12
Ginkgo biloba has a proven benefit

Comment on: Tian et al. Alzheimer's Research & Therapy 2010, 2:30
Traumatic brain injury and Alzheimer¿s disease

Comment on: Gavett et al. Alzheimer's Research & Therapy 2010, 2:18

Alzheimer's Research and Therapy Chromosome 9

Alzheimer's Research & Therapy on Twitter

Aims & scope

Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.